REGN 3767

Drug Profile

REGN 3767

Alternative Names: REGN3767

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 06 Jan 2017 Phase-I clinical trials in Cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral) (NCT03005782)
  • 01 Nov 2016 Phase-I clinical trials in Cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT03005782)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top